Dare Bioscience
dare regulatory strategy following clinical development dar intends to leverage the existing safety and efficacy data on the active ingredients in dare estradiol and progesterone to utilize the food and drug administration pathway to obtain marketing approval of dare in the dar intends to seek approval of dare for the treatment of moderate to severe due to menopause in women with intact uteri based on communications with the and the topline data from the dare phase study dar believes approval of dare for that indication is achievable via the pathway supported by a single placebo controlled phase clinical trial of dare and a scientifically justified bridge via a relative trial between dare and the selected listed estradiol and progesterone drugs ongoing activities to support progressing directly into a single phase study to support registration include manufacturing and non clinical studies to support the submission and the planned opening phase study dare strategy | Dare Bioscience
Company
Deck Type
Sector
Industry
Deck date
February 2023
Slide
42 of 54
Related slides by other companies
MAIA Biotechnology
Investor Presentation
January 2024
investment overview an | MAIA Biotechnology
AstraZeneca
Investor Day
September 2022
supports further indication expansion | AstraZeneca
Equillium
Investor Presentation
December 2023
phase study of in adults with moderate to severe target product profile alternative to with at least comparable efficacy patient administered weekly weekly subcutaneous injection similar to | Equillium
Erasca
Investor Presentation
August 2023
proposed pivotal phase trial designs creative strategy includes high randomized melanoma trial and tissue agnostic indication | Erasca
Other recent decks by Dare Bioscience
See all presentations (5 decks)
Results
November 2023
Investor Presentation
August 2023
Investor Presentation
July 2023
Investor Presentation
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights